News

Published on 14 Dec 2022 on Benzinga via Yahoo Finance

Penny Stock OpGen Surges After UTI Panel Test Meets Primary Goal In Clinical Trial


Article preview image

OpGen Inc (NASDAQ: OPGN) announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.OpGen's Unyvero UTI Panel tests for a broad range of bacterial and fungal pathogens and antimicrobial resistance markers directly from urine specimens.The test aims at the quantitative detection of microorganisms.The trial was designed to compare the performance of the Unyvero UTI Panel for detecting urinary tract infections (UTI) using clean-catch or catheter-related urine samples.The study met the primary endpoint and exhibited an overall weighted average sensitivity of 96.4% and an overall weighted average specificity of 97.4% when compared against each trial site's standard of care microbiology results.Related: OpGen Stock Gains On FDA Approval, Interim Q3 Sales.The trial included 1,858 prospective and archived samples and has run over 3,300 Unyvero cartridges, including controls and reproducibility tests performed at the different trial sites.Based on all the data generated and analyzed, OpGen will start preparing a De Novo request package for submission to the FDA in due course.OpGen intends to present data at a future conference and submit it for a peer-reviewed publication.Price Action: OPGN shares are up 146.30% at $0.30 on the last check Tuesday.

See more from Benzinga

NASDAQ.OPGN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
What's Going On With Tempest Therapeutics Stock? - Tempest Therapeutics (NASDAQ:TPST)

Tempest Therapeutics Inc TPST shares are trading lower Thursday. The company sold shares as part ...

Benzinga 12 Oct 2023

ChatGPT Parent OpenAI Aims At Budget-Friendly AI Innovations, Novo Nordisk's Popular Diabetes Drug...

Bloomberg Apple and Suppliers Face Unanticipated Sales Slump Despite New Launches

Benzinga via Yahoo Finance 12 Oct 2023

US Stocks Edge Lower; Consumer Price Index Increases 0.4% For September - OpGen (NASDAQ:OPGN), RVL ...

U.S. stocks traded slightly lower this morning, following the release of CPI data on Thursday. Fo...

Benzinga 12 Oct 2023

Bet on DuPont Analysis to Pick 5 Stocks for Stellar Returns

Return on equity (ROE) is one of the most favored metrics of investors. It is a profitability rat...

Zacks via Yahoo Finance 21 Jun 2023

Penny Stock OpGen Surges After UTI Panel Test Meets Primary Goal In Clinical Trial

OpGen Inc (NASDAQ: OPGN) announced topline data from its Unyvero urinary tract infections (UTI) c...

Benzinga via Yahoo Finance 14 Dec 2022

Analysts’ New Coverage for June 2nd (ABIO, ACU, AHPI, CALT, CNTB, CRAYF, CREX, EVFM, GALT, GLYC)

Analysts’ new coverage for Thursday, June 2nd: StockNews.com initiated coverage on shares of ARCA...

ETF DAILY NEWS 2 Jun 2022

Analysts’ Upgrades for June 1st (BME, BMRRY, BPMC, DHR, DLTR, DMRC, FINV, FMX, GCHEF, HBCP)

Analysts’ upgrades for Wednesday, June 1st: B&M European Value Retail (LON:BME) was upgraded by...

ETF DAILY NEWS 1 Jun 2022

Research Analysts’ Price Target Changes for May 31st (AFLYY, BHP, BTI, BURBY, CBWBF, CGC, CNVVY,...

BHP Group (NYSE:BHP) had its price target cut by Deutsche Bank Aktiengesellschaft from GBX 2,400...

ETF DAILY NEWS 31 May 2022

OpGen, Inc. (OPGN) Reports Q1 Loss, Lags Revenue Estimates

OpGen, Inc. (OPGN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus E...

Zacks via Yahoo Finance 13 May 2022

Equities Research Analysts’ New Coverage for May 9th (ADXS, AHPI, AIRC, ANGPY, APLD, BRBR, CRM,...

Equities Research Analysts’ new coverage for Monday, May 9th: StockNews.com began coverage on sha...

ETF DAILY NEWS 9 May 2022